Dalbavancin
General Information
Restricted formulary antimicrobial: For details see OUH netFormulary
AWaRe antibiotic classification: 'Reserve'. All indications to be discussed with Micro/ID
Renal and hepatic impairment
Renal impairment (Note: dose ranges use creatinine clearance, rather than eGFR)
Creatinine Clearance 30ml/min and over: Dose as in normal renal function
Creatinine Clearance less than 30ml/min: See table below:
| Where creatinine clearance less than 30ml/min | Dose of dalbavancin IV |
| Day 1 of treatment |
1g single dose Repeat U&Es on day 8 |
|
Day 8 of treatment: If creatinine clearance improved i.e 30ml/min and over |
500mg single dose |
|
Day 8 of treatment: If creatinine clearance remains less than 30ml/min |
375mg single dose |
Haemodialysis:
|
Dose of dalbavancin IV |
|
| Haemodialysis (3 times/week) |
Dose as in normal renal function Can be administered without regard to the timing of haemodialysis. |
Hepatic impairment
Mild hepatic impairment (Child-Pugh A): No dose adjustment
Moderate or severe hepatic impairment (Child-Pugh B & C): Use with caution as no data are available to determine appropriate dosing.
Pregnancy and breastfeeding
Pregnancy
Discuss with pharmacy.
Breastfeeding
Discuss with pharmacy.
References
- ADVANZ Pharma. Summary of Product Characteristics (SPC). Xydalba 500 mg powder for concentrate for solution for infusion. Last revision of the text 10/2020 Accessed at https://www.medicines.org.uk/emc/product/2270/smpc on 8/11/21